Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Medipal HD Reports Sharp Increase in Operating Profits in First Half
November 2, 2012
- Eisai Suffers Double-Digit Sales, Profit Falls in 1st Half as Mainstay Drugs Slump
November 2, 2012
- Sales Target for Prasugrel Achievable Despite Add’l Indication Dropped: Daiichi Sankyo Pres. Nakayama
November 2, 2012
- Shionogi Licenses Alzheimer’s Disease Treatment to Janssen Pharmaceuticals of US
November 2, 2012
- DSP’s 1st Half Sales Up Mere 0.4 % due to Stagnant Domestic Sales, Profits Show Double-Digit Increase
November 2, 2012
- Takeda’s 1st Half Operating Profits Down 48% due to M&A Costs
November 1, 2012
- FDA Accepts Supplemental NDAs for Latuda for Bipolar Depression: DSP
November 1, 2012
- Takeda’s Japan Sales Ratio Likely to Fall to Mid-30% Range: President Hasegawa
November 1, 2012
- EpiPen Marketing Approval Transferred to Pfizer from Mylan
November 1, 2012
- Daiichi Sankyo’s Semiannual Sales Up 6.2% Driven by Ranbaxy
November 1, 2012
- Japanese Pharmaceutical Industry Should Speak More Strongly in Favor of TPP: Paul King
November 1, 2012
- Bayer Announces Positive Results of PIII Trials of Riociguat in Patients with CTEPH, PAH
October 31, 2012
- Mochida, MTPC See Signs of Sales Growth for Lexapro after Lifting of Long-Term Prescription Ban
October 31, 2012
- All-Case Surveillance Lifted for Humira for Crohn’s Disease: Abbott Japan/Eisai
October 31, 2012
- Asahi Kasei Pharma Launches Global PIII Trial for Recomodulin
October 31, 2012
- Astellas Launches Quadruple Vaccine Quattrovac on October 31
October 31, 2012
- Takeda Files NDA in Japan for Cetilistat for Treatment of Obesity
October 31, 2012
- Mitsubishi Tanabe Reports Growth in 1st-Half Sales with Boost from Remicade, Telavic
October 31, 2012
- Kyowa Hakko Bio to Set Up New Plant in Thailand in Response to Rising Demand for Amino Acids
October 30, 2012
- Equity Participation in ViiV Hoped to Cover Patent Loss of Crestor: Shionogi Pres. Teshirogi
October 30, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…